{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T22:18:55Z","timestamp":1768774735709,"version":"3.49.0"},"reference-count":36,"publisher":"FapUNIFESP (SciELO)","issue":"4","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz J Med Biol Res"],"DOI":"10.1590\/1414-431x20209369","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T14:29:18Z","timestamp":1614781758000},"source":"Crossref","is-referenced-by-count":4,"title":["An open-label randomized clinical trial to evaluate the efficacy of everolimus versus tacrolimus in triple maintenance immunosuppressive therapy for kidney transplant patients"],"prefix":"10.1590","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-1366","authenticated-orcid":false,"given":"B.P.S.","family":"Assis","sequence":"first","affiliation":[{"name":"Hospital Universit\u00e1rio da Faculdade de Ci\u00eancias M\u00e9dicas,  Brasil; Faculdade de Ci\u00eancias M\u00e9dicas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7912-5268","authenticated-orcid":false,"given":"M.F.","family":"Lasmar","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio da Faculdade de Ci\u00eancias M\u00e9dicas,  Brasil; Faculdade de Ci\u00eancias M\u00e9dicas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-0666","authenticated-orcid":false,"given":"R.A.","family":"Fabreti-Oliveira","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias M\u00e9dicas,  Brasil; IMUNOLAB Ltda - Laborat\u00f3rio de Histocompatibilidade,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9996-4405","authenticated-orcid":false,"given":"S.A.","family":"Araujo","sequence":"additional","affiliation":[{"name":"Instituto de Nefropatologia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-8191","authenticated-orcid":false,"given":"J.","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias M\u00e9dicas,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1201-9449","authenticated-orcid":false,"given":"D.C.","family":"Wanderley","sequence":"additional","affiliation":[{"name":"Instituto de Nefropatologia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7008-4022","authenticated-orcid":false,"given":"E.","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Faculdade de Ci\u00eancias M\u00e9dicas,  Brasil; IMUNOLAB Ltda - Laborat\u00f3rio de Histocompatibilidade,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2021]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e111128","DOI":"10.1371\/journal.pone.0111128","article-title":"The tacrolimus metabolism rate influences renal function after kidney transplantation","volume":"9","author":"Tholking G","year":"2014","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg H","year":"2007","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21767\/2472-5056.100027","article-title":"The use of everolimus in renal-transplant patients with nephrotoxicity by calcineurin inhibitors in our center: case report","volume":"2","author":"Kozaki K","year":"2017","journal-title":"J Clin Exp Nephrol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/j.1600-6143.2006.01340.x","article-title":"Long-term renal allograft function on a tacrolimus-based, PRED-free maintenance immunosuppression comparing sirolimus vs. MMF","volume":"6","author":"Gallon L","year":"2006","journal-title":"Am J Transplant"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1432-2277.2006.00414.x","article-title":"12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients","volume":"20","author":"Tedesco-Silva Jr H","year":"2007","journal-title":"Transplant Int"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":"Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness","volume":"85","author":"Chan L","year":"2008","journal-title":"Transplantation"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"a015487","DOI":"10.1101\/cshperspect.a015487","article-title":"Immunosuppressive drug therapy","volume":"3","author":"Hartono C","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.tp.0000203894.53714.27","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate versus cyclosporine\/sirolimus in renal transplantation: three-year analysis","volume":"81","author":"Ciancio G","year":"2006","journal-title":"Transplantation"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.tp.0000167757.63922.42","article-title":"A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year","volume":"80","author":"Mendez R","year":"2005","journal-title":"Transplantation"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/TP.0b013e3181bb43ec","article-title":"Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial","volume":"88","author":"Salvadori M","year":"2009","journal-title":"Transplantation"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1016\/j.transproceed.2012.06.072","article-title":"Conversion to everolimus in kidney transplant recipients: to believe or not believe?","volume":"44","author":"Cotovio P","year":"2012","journal-title":"Transplant Proc"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study","volume":"80","author":"Lorber MI","year":"2005","journal-title":"Transplantation"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1432-2277.2009.01010.x","article-title":"Effect of everolimus on skin cancers in calcineurin inhibitor-treated heart transplant recipients","volume":"23","author":"Euvrard S","year":"2010","journal-title":"Transplant Int"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2011.03674.x","article-title":"Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials","volume":"1","author":"Brennan DC","year":"2011","journal-title":"Am J Transplant"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"mTOR signaling in growth and metabolism","volume":"124","author":"Wullschleger S","year":"2006","journal-title":"Cell"},{"key":"ref16","first-page":"91","article-title":"Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and\/or sorafenib","volume":"4","author":"Copin C","year":"2010","journal-title":"Biologics"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","article-title":"Therapeutic drug monitoring of everolimus: a consensus report","volume":"38","author":"Shipkova M","year":"2016","journal-title":"Ther Drug Monit"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5500\/wjt.v6.i1.183","article-title":"Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation","volume":"6","author":"Baroja-Mazo A","year":"2016","journal-title":"World J Transplant"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5500\/wjt.v8.i5.150","article-title":"Introduction of everolimus in kidney transplant recipients at a later posttransplant stage","volume":"8","author":"Uchida J","year":"2018","journal-title":"World J Transplant"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trre.2005.10.005","article-title":"Everolimus (Certican\u00ae) in renal transplantation: a review of clinical trial data, current usage and future directions","volume":"20","author":"Pascual J","year":"2006","journal-title":"Transplant Rev"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e0170246","DOI":"10.1371\/journal.pone.0170246","article-title":"Efficacy and safety of everolimus for maintenance immunosuppression of kidney transplantation: a metanalysis of randomized controlled trials","volume":"12","author":"Liu J","year":"2017","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev-immunol-020711-075024","article-title":"Regulation of immune responses by mTOR","volume":"30","author":"Powell JD","year":"2012","journal-title":"Ann Rev Immunol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/ajt.14186","article-title":"Early conversion from calcineurin inhibitor to Everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE trial","volume":"17","author":"Fijter JW","year":"2017","journal-title":"Am J Transplant"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.transproceed.2013.10.041","article-title":"Kidney transplantation: evaluation and clinical outcome of 237 patients at low, medium, high or strong high risk of rejection","volume":"46","author":"Nascimento E","year":"2014","journal-title":"Transplant Proc"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MOT.0b013e3283636ddf","article-title":"The current role of human leukocyte antigen matching in kidney transplantation","volume":"18","author":"Susal C","year":"2013","journal-title":"Curr Opin Organ Transplant"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 Meeting Report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions","volume":"14","author":"Haas M","year":"2014","journal-title":"Am J Transplant"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ajt.14107","article-title":"The Banff 2015 kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology","volume":"17","author":"Loupy A","year":"2017","journal-title":"Am J Transplant"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12882-019-1497-5","article-title":"Effects of immunotherapy induction on outcome and graft survival of kidney-Transplanted patients with different immunological risk of rejection","volume":"20","author":"Lasmar MF","year":"2019","journal-title":"BMC Nephrol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg H","year":"2007","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION Study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"Flechner SM","year":"2011","journal-title":"Am J Transplant"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"Lim WH","year":"2014","journal-title":"Am J Transplant"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/tri.12688","article-title":"CD25 blockade in kidney transplant patients randomized to standard-doseor high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen","volume":"29","author":"Thibault G","year":"2016","journal-title":"Transplant Int"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/ajt.14744","article-title":"The first 9 years of kidney paired donation through the National Kidney Registry: characteristics of donors and recipients compared with National Live Donor Transplant Registries","volume":"18","author":"Flechner SM","year":"2018","journal-title":"Am J Transplant"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson TS","year":"2006","journal-title":"Am J Transplant"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2165\/11319260-000000000-00000","article-title":"Immunosuppresive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancies and infection","volume":"69","author":"Marc\u00e9n R","year":"2009","journal-title":"Drugs"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"403280","DOI":"10.1155\/2013\/403280","article-title":"Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors","volume":"2013","author":"Zaza G","year":"2013","journal-title":"Clin Dev Immunol"}],"container-title":["Brazilian Journal of Medical and Biological Research"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/bjmbr\/v54n4\/1414-431X-bjmbr-54-4-e9369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T12:03:29Z","timestamp":1615205009000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-879X2021000400611&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021]]}},"alternative-id":["S0100-879X2021000400611"],"URL":"https:\/\/doi.org\/10.1590\/1414-431x20209369","relation":{},"ISSN":["1414-431X","0100-879X"],"issn-type":[{"value":"1414-431X","type":"electronic"},{"value":"0100-879X","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"e9369"}}